Your browser is no longer supported. Please, upgrade your browser.
Settings
ARDX [NASD]
Ardelyx, Inc.
Index- P/E- EPS (ttm)-1.14 Insider Own1.00% Shs Outstand97.18M Perf Week3.57%
Market Cap168.80M Forward P/E- EPS next Y-1.09 Insider Trans-2.83% Shs Float67.05M Perf Month-77.04%
Income-105.10M PEG- EPS next Q-0.37 Inst Own87.80% Short Float14.74% Perf Quarter-76.20%
Sales12.90M P/S13.09 EPS this Y28.50% Inst Trans0.32% Short Ratio1.21 Perf Half Y-74.37%
Book/sh1.35 P/B1.29 EPS next Y48.60% ROA-50.80% Target Price- Perf Year-69.84%
Cash/sh1.84 P/C0.95 EPS next 5Y30.00% ROE-78.60% 52W Range1.51 - 9.23 Perf YTD-73.11%
Dividend- P/FCF- EPS past 5Y4.00% ROI-51.30% 52W High-81.15% Beta1.80
Dividend %- Quick Ratio4.90 Sales past 5Y-20.60% Gross Margin91.20% 52W Low15.23% ATR0.47
Employees129 Current Ratio4.90 Sales Q/Q450.00% Oper. Margin- RSI (14)16.06 Volatility10.82% 6.80%
OptionableYes Debt/Eq0.39 EPS Q/Q-35.50% Profit Margin- Rel Volume11.89 Prev Close1.71
ShortableYes LT Debt/Eq0.26 EarningsMay 06 BMO Payout- Avg Volume8.19M Price1.74
Recom1.40 SMA20-67.82% SMA50-73.26% SMA200-73.79% Volume83,731,688 Change1.75%
Jul-21-21Downgrade Jefferies Buy → Hold $11 → $2
Jul-20-21Downgrade Wedbush Outperform → Neutral $3
Jul-20-21Downgrade Piper Sandler Overweight → Neutral $14 → $4
Mar-23-21Initiated Wedbush Outperform $14
Jan-06-21Initiated Cantor Fitzgerald Overweight $14
Oct-20-20Resumed Citigroup Buy $13
Feb-18-20Resumed Jefferies Buy $11
Feb-12-20Initiated Citigroup Buy $13
Feb-10-20Initiated Cowen Outperform
Apr-08-19Initiated Piper Jaffray Overweight $15
Aug-24-18Initiated Jefferies Buy $7
Mar-19-18Resumed Leerink Partners Outperform $13
Nov-29-17Reiterated Citigroup Buy $16 → $17
Nov-22-17Reiterated Ladenburg Thalmann Buy $19 → $16
Oct-17-17Resumed Leerink Partners Outperform
Mar-31-16Initiated Ladenburg Thalmann Buy
Mar-09-16Initiated Cantor Fitzgerald Buy $19
Mar-03-16Initiated Citigroup Buy
Aug-01-21 11:45AM  
Jul-30-21 09:20PM  
09:12PM  
08:41PM  
07:19PM  
03:38PM  
03:20PM  
02:10PM  
Jul-29-21 04:01PM  
Jul-28-21 08:29PM  
04:21PM  
10:45AM  
Jul-26-21 08:12PM  
Jul-23-21 11:00AM  
Jul-22-21 11:00AM  
08:00AM  
01:23AM  
Jul-21-21 08:20PM  
08:00PM  
06:21PM  
04:52PM  
11:00AM  
11:00AM  
10:02AM  
03:17AM  
01:15AM  
Jul-20-21 05:56PM  
10:37AM  
08:27AM  
08:25AM  
05:12AM  
04:28AM  
03:24AM  
Jul-19-21 06:28PM  
05:26PM  
04:53PM  
04:01PM  
Jun-18-21 01:21AM  
Jun-07-21 08:00AM  
May-25-21 08:00AM  
May-13-21 01:12AM  
01:10AM  
May-06-21 09:35AM  
08:00AM  
Apr-30-21 11:25AM  
Apr-29-21 05:06PM  
04:15PM  
Apr-16-21 04:01PM  
08:32AM  
Apr-14-21 03:00PM  
08:00AM  
Apr-12-21 08:00AM  
Apr-07-21 01:46AM  
Apr-01-21 08:59AM  
Mar-30-21 04:01PM  
Mar-26-21 02:34PM  
Mar-15-21 08:00AM  
Mar-08-21 09:25AM  
08:00AM  
Mar-02-21 12:29AM  
Mar-01-21 07:04PM  
Feb-26-21 12:30PM  
Feb-17-21 08:00AM  
Feb-08-21 10:11AM  
Jan-16-21 01:34AM  
Dec-18-20 08:28PM  
Dec-11-20 12:58AM  
Nov-23-20 08:00AM  
Nov-10-20 08:00AM  
Nov-06-20 08:00AM  
05:28AM  
Nov-05-20 08:00AM  
Oct-28-20 12:33PM  
Oct-22-20 10:00AM  
08:00AM  
Oct-12-20 08:00AM  
Oct-02-20 07:02AM  
Sep-29-20 11:23AM  
Sep-15-20 08:00AM  
Sep-08-20 08:00AM  
Aug-27-20 08:41AM  
Aug-06-20 11:45AM  
08:00AM  
Aug-03-20 10:55AM  
08:00AM  
Jul-28-20 07:55AM  
Jul-08-20 12:00PM  
Jun-30-20 08:00AM  
Jun-28-20 08:30AM  
Jun-19-20 12:45PM  
Jun-15-20 08:00AM  
Jun-09-20 08:45PM  
Jun-08-20 04:01PM  
May-26-20 09:00AM  
May-21-20 05:23PM  
May-18-20 04:01PM  
May-12-20 10:44AM  
May-11-20 12:00PM  
May-10-20 08:16AM  
May-07-20 04:02PM  
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jacobs Jeffrey WChief Scientific OfficerJun 15Option Exercise0.547,5004,050131,551Jun 17 04:32 PM
Jacobs Jeffrey WChief Scientific OfficerJun 15Sale7.297,50054,658124,051Jun 17 04:32 PM
Rosenbaum David P.Chief Development OfficerMay 28Sale7.223,06222,09826,750Jun 02 07:23 PM
Rosenbaum David P.Chief Development OfficerMay 20Sale7.091571,11329,812May 21 04:49 PM
Rosenbaum David P.Chief Development OfficerMay 20Sale7.096124,338159,435May 21 04:49 PM
Rodriguez SusanChief Commercial OfficerMay 20Sale7.096114,33145,303May 21 04:49 PM
RAAB MICHAELPresident & CEOMay 20Sale7.092,53417,960214,754May 21 04:47 PM
Renz Justin AChief Financial OfficerMay 20Sale7.096124,33840,678May 21 04:48 PM
Blanks RobertSee RemarksMay 20Sale7.096124,338106,954May 21 04:46 PM
GRAMMER ELIZABETH ASee RemarksMay 20Sale7.095083,601102,912May 21 04:46 PM
Jacobs Jeffrey WChief Scientific OfficerMay 20Sale7.097215,110124,051May 21 04:47 PM
Rosenbaum David P.Chief Development OfficerApr 06Sale8.005,00040,000160,047Apr 08 06:20 PM
Blanks RobertSee RemarksFeb 22Sale6.885934,081112,729Feb 24 04:50 PM
Jacobs Jeffrey WChief Scientific OfficerFeb 22Sale6.887024,832124,772Feb 24 04:41 PM
Rosenbaum David P.Chief Development OfficerFeb 22Sale6.881931,32829,969Feb 24 04:38 PM
Rosenbaum David P.Chief Development OfficerFeb 22Sale6.886124,212165,047Feb 24 04:38 PM
Rodriguez SusanChief Commercial OfficerFeb 22Sale6.886114,20545,914Feb 24 04:40 PM
Renz Justin AChief Financial OfficerFeb 22Sale6.886084,18541,290Feb 24 04:37 PM
RAAB MICHAELPresident & CEOFeb 22Sale6.882,53417,440217,288Feb 24 04:39 PM
GRAMMER ELIZABETH ASee RemarksFeb 22Sale6.885043,469103,420Feb 24 04:36 PM
Jacobs Jeffrey WChief Scientific OfficerDec 21Sale6.883,94927,15392,862Dec 22 04:10 PM
GRAMMER ELIZABETH ASee RemarksDec 14Option Exercise2.3241,00095,120113,527Dec 15 04:22 PM
GRAMMER ELIZABETH ASee RemarksDec 14Sale7.3041,000299,30072,527Dec 15 04:22 PM
GRAMMER ELIZABETH ASee RemarksDec 11Option Exercise2.321,0002,32073,527Dec 15 04:22 PM
GRAMMER ELIZABETH ASee RemarksDec 11Sale7.301,0007,30072,527Dec 15 04:22 PM
MOTT DAVID MDirectorDec 10Buy5.89170,0001,000,841417,284Dec 10 06:22 PM
Jacobs Jeffrey WSVP, Technical OperationsSep 16Sale6.0510,00060,50096,811Sep 17 06:30 PM
Rodriguez SusanChief Commercial OfficerSep 16Sale6.116,08737,16413,913Sep 17 06:35 PM
Rosenbaum David P.Chief Development OfficerSep 15Sale5.513,47019,13121,662Sep 17 06:34 PM
Rosenbaum David P.Chief Development OfficerSep 15Sale5.5234,656191,301133,047Sep 17 06:34 PM
Blanks RobertSee RemarksSep 15Sale5.4534,685189,18280,710Sep 17 06:33 PM
RAAB MICHAELPresident & CEOSep 15Sale5.61106,337596,285104,720Sep 17 06:31 PM
Renz Justin AChief Financial OfficerSep 15Sale5.493,71420,3739,286Sep 17 06:32 PM
GRAMMER ELIZABETH ASee RemarksSep 15Sale5.3728,810154,57472,527Sep 17 06:31 PM
Jacobs Jeffrey WSVP, Technical OperationsSep 15Sale5.5340,804225,589106,811Sep 17 06:30 PM
Blanks RobertSee RemarksSep 01Sale5.582,04911,425115,395Sep 03 05:03 PM